Ocrevus Zunovo™ (ocrelizumab/hyaluronidase-ocsq) – New subcutaneous formulation approval
September 13, 2024 - Halozyme announced that Roche received FDA approval of Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq), for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease; and primary progressive MS.
Top